Nialamide
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.000.073 |
| Chemical and physical data | |
| Formula | C16H18N4O2 |
| Molar mass | 298.346g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Nialamide(Niamid,Niamide,Nuredal,Surgex) is a non-selective,irreversiblemonoamine oxidase inhibitor(MAOI) of thehydrazineclass that was used as anantidepressant.[2]It was withdrawn byPfizerseveral decades ago due to the risk ofhepatotoxicity.[3][4]
Side effects include agitation and insomnia, less frequently dry mouth, dizziness, blurred vision, and hypomania, and rarelyleukopeniaand hepatitis. As with other MAOIs, ahypertensive crisiscan be triggered by co-ingestion oftyramine.It is metabolized intoisoniazid,an anti-tuberculosisagent, and so is contraindicated in patients with tuberculosis. The recommended dosage range is 75 to 200 mg per day, with maintenance doses as low as 12.5 mg every other day.[5]
The antiatherogenic activity of nialamide was used to designpyridinolcarbamate.[6]
See also[edit]
References[edit]
- ^Anvisa(2023-03-31)."RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial"[Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese).Diário Oficial da União(published 2023-04-04).Archivedfrom the original on 2023-08-03.Retrieved2023-08-16.
- ^William Andrew Publishing (1 December 2006).Pharmaceutical Manufacturing Encyclopedia(3rd ed.). Elsevier. pp. 2935–.ISBN978-0-8155-1856-3.
- ^Gad SC (26 April 2012).Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition.CRC Press. pp. 138–.ISBN978-1-4398-4567-7.
- ^Shorter E (28 September 2008).Before Prozac: The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry.Oxford University Press. pp. 137–.ISBN978-0-19-970933-5.
- ^Council on Drugs (1971).AMA Drug Evaluations(Report). Chicago:American Medical Association.LCCN75147249.RetrievedApril 5,2021.
- ^Bencze WL, Hess R, DeStevens G (6 December 2012)."Hypolipidemic Agents".Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques.Vol. 13. Springer Science & Business Media. pp. 217–92.doi:10.1007/978-3-0348-7068-9_5.ISBN9783642661907.PMID4982663.Retrieved3 October2017.
{{cite book}}:|journal=ignored (help)